Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma

Hoshi,Manabu; Oebisu,Naoto; Takada,Jun; Iwai,Tdashi; Nakamura,Hiroaki

doi:10.3892/ol.2015.2844

Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma

Authors:
- Manabu Hoshi
- Naoto Oebisu
- Jun Takada
- Tdashi Iwai
- Hiroaki Nakamura
View Affiliations

Affiliations: Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Published online on: January 5, 2015 https://doi.org/10.3892/ol.2015.2844
Pages: 1409-1411

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study presents the case of a 59‑year‑old male with advanced‑stage renal cell carcinoma and bone metastases in the proximal femur and ilium (cT3aN3M1; stage IV). Resection of the primary renal cell cancer and palliative surgery with a γ‑nail for an impending fracture of the right proximal femur were performed, followed by radiotherapy. Sorafenib, a multi‑kinase inhibitor that blocks the raf and tyrosine kinases of the vascular endothelial and platelet‑derived growth factor receptors, was administered for 9 months, resulting in a marked improvement in the metastatic ilium and a reduction in the extent of the lung metastases. The patient suffered minor adverse effects, including a skin rash and mild diarrhea, but remained alive at the time of follow‑up at 36 months post‑surgery. Sorafenib demonstrated efficacy against the bone metastasis of metastatic renal cell carcinoma.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Zekri J, Ahmed N, Coleman RE and Hancock BW: The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 19:379–382. 2001.PubMed/NCBI
3	Kyoda Y, Kobayashi K, Hirobe M, et al: Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment. Int J Clin Oncol. 19:146–151. 2014. View Article : Google Scholar
4	Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
5	Motzer RJ, Bander NH and Nanus DM: Renal cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
6	Woodward E, Jagdev S, McParland L, et al: Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 48:160–166. 2011. View Article : Google Scholar
7	Weiss RJ, Ekström W, Hansen BH, et al: Pathological subtrochanteric fractures in 194 patients: a comparison of outcome after surgical treatment of pathological and non-pathological fractures. J Surg Oncol. 107:498–504. 2013. View Article : Google Scholar
8	Negrier S, Perol D, Ravaud A, et al: Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 110:2468–2477. 2007. View Article : Google Scholar : PubMed/NCBI
9	McDermott DF, Regan MM, Clark JI, et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 23:133–141. 2005. View Article : Google Scholar
10	Escudier B, Szczylik C, Hutson TE, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 27:1280–1289. 2009. View Article : Google Scholar : PubMed/NCBI
11	Angelucci A, Gravina GL, Rucci N, et al: Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer. 13:197–210. 2006. View Article : Google Scholar : PubMed/NCBI
12	Normanno N and Gullick WJ: Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer. 13:3–6. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lin PP, Mirza AN, Lewis VO, et al: Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 89:1794–1801. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sugiura H, Yamada K, Sugiura T, Hida T and Mitsudomi T: Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 466:729–736. 2008. View Article : Google Scholar : PubMed/NCBI